← Back to headlines
Pharvaris Stock Jumps 27% on Positive Hereditary Angioedema Trial
Pharvaris shares surged after the company announced a late-stage trial win for its hereditary angioedema drug, while Roivant reported positive phase 2 results for mosliciguat and Genflow Biosciences met its primary endpoint in a SLAB clinical trial.
8 Sept, 06:31 — 8 Sept, 11:51
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (37/100)3 sources25/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center2
Center (2)
investing-commorningstar
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US3
ℹAll sources from US region
Sources
Showing 2 of 3 sources
morningstar6h ago
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met - Morningstar
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met Morningstar
Read full article →seeking-alphaMixed46m ago
Pharvaris rises on late-stage trial win for hereditary angioedema drug
Read full article →Coverage Timeline
First report: morningstar · 8 Sept, 06:31|Full coverage: 3 · 5h|Window: 5h
Left-leaningCenterRight-leaning
Related Stories
Amazon Taps Banks for First Sterling Bond Offering
32m ago
Novartis Shares Plunge After Late-Stage Trial Fails for Neuromuscular Drug Candidate
36m ago
Hindustan Copper Shares Surge as Copper Prices Hit Record High
37m ago
GE Aerospace Agrees to Acquire Precision Castings Supplier CPP for $12 Billion
40m ago